All News
Or to quote the great Murray Urowitz @UHN "a #lupus pregnancy has four trimesters"! #ACR23 https://t.co/Iw2S81tiTH
Ian N Bruce ( View Tweet)
✅ Question to YOU attending #ACR23 ➡️ We're almost at the end of 2023 ⌛and many great #lupus data are being presented at @ACRheum Convergence 2023 in San Diego 👍 What would YOU update/change 🔄 regarding the management of #lupus in 2024 compared to 2023? 🧭 https://t.co/xpSXjuDjyr
Laurent ARNAUD ( View Tweet)
Real-life data about the PEXIVAS reduced-dose glucocorticoid regimen in #granulomatosis with polyangiitis and microscopic #polyangiitis (Abstract 0725 https://t.co/7x34Hr0OMP)
@TerrierBen
#ACR23
#ACRambassador https://t.co/D8UfZvXQCl
Alessia Alunno ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on SpA Update: Radiographic and Non-Radiographic AS - Dr. Alexis Ogdie
1. Workup of inflammatory back pain: History, exam, CRP, HLA-B27, SI joint films, MRI pelvis (STIR images, no need for contrast). Response to NSAIDs not actually… https://t.co/M0W6UNsPxF https://t.co/7k3xl1RXZz
Paul Sufka, MD psufka ( View Tweet)
ABS0524:
⭐️Benefit of Certolizumab (CZP) over standard non-biologic tx in reducing acute anterior uveitis (AAU) flares among high risk pts w/ axSpA
➡️active dz, HLAB27+, 2 or more AAU flares
⭐️CZP reduced AAU flare rate by 87%
#ACR23 @RheumNow
#ACRBest https://t.co/rW0N18agMO
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Takeaways from #ACR23 #ReviewCourse session on Update on Relapsing Polychondritis - Dr. Marcela Ferrada
1. Be aware of common/uncommon manifestations (see slide). Affects more than just the ear!!!
2. Collagen II antibodies: not really sensitive or specific for diagnosis. Biopsy… https://t.co/f5xGtcMzk3 https://t.co/xVigSabXDb
Paul Sufka, MD psufka ( View Tweet)
Are we tapering steroids too rapidly? Real world experience: steroid tapering in severe #AAV based on #PEXIVAS protocol noted higher rates of dz progression, relapse, ESRD, death. Risk greatest when creatinine > 300umol/L and w/RTX induction #Plenary1 #ACR23 Abst#0725 #ACrBest https://t.co/Rtv7vkzUUD
TheDaoIndex KDAO2011 ( View Tweet)
ARDs increase risk for CVE in pregnancy, the highest being APS, SLE (with LN and APS) and RA. Close monitoring not only during but also after pregnancy is required. #Plenary #ACR23 https://t.co/W3CSjccSno
Adela Castro AdelaCastro222 ( View Tweet)
🔥 Absolute masterclass @philseo in the Clinical Year in Review #ACR23
➡️ Certain subpopulations have lower risk of AE with Tofacitinib
➡️ Knee OA 📈 75% by 2050
➡️ Exciting novel approaches in Rx of IA in development
➡️Better clinical trial endpoints needed for SLE https://t.co/5cjbZLPsCM
Caoilfhionn Connolly ( View Tweet)
#Denosumab and what to do IF you stop it
#ACR23 #osteoporosis #Bisphosphonate #CTX https://t.co/qwdQQjJJlb
Dr Gurdeep S Dulay ( View Tweet)
Efficacy and Safety of Targeted Therapies in #VEXAS Syndrome: Retrospective Study from the French VEXAS Group :)
#ACR23 late breaking poster - the figure says it all
https://t.co/qahDDPLois https://t.co/ueb4aG8t77
Latika LatikaGupta_ ( View Tweet)
ABS0538:
⭐️Characteristics of difficult-to-treat (D2T) axSpA pts:
➡️HLAB27(-)
➡️smokers
➡️shorter symptom duration
➡️more enthesitis
➡️IBD
➡️concomitant NSAID use
➡️Co-morbidities (HTN, HLD, fibro, depress/anxiety)
#ACR23 @RheumNow https://t.co/TqEVBeaJpb
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Yield of repeated assessments of SpA features in patients with CBP suspected of axSpA was modest for the increase of new definite axSpA diagnosis at 2y. Sacroilitis on MRI, good response to NSAIDs at BL most predictive of axSpA, ML Marques #ACR23 @RheumNow https://t.co/LQ5llML11M https://t.co/PYcCDypI7c
Dr. Antoni Chan ( View Tweet)
What a great pleasure to meet with the most amazing @RheumNow team on site at #ACR23 so glad to meet Shannon, Mitzi, John @Yuz6Yusof @Janetbirdope and looking forward to sharing the learnings from the conference https://t.co/ovXXLxDLKW
Dr. Antoni Chan ( View Tweet)
Pregnant women with ARDs esp. SLE nephritis and primary APS have significantly higher risks for acute CVEs compared to those without these conditions. 25-30% of CVEs occurred during the postpartum period, Dhital R Abst#0722 #ACR23 #ACRBest @RheumNow https://t.co/m9FjsAu64N https://t.co/1dyTzgH97A
Dr. Antoni Chan ( View Tweet)
Reduced-dose GC regimen in severe GPA or MPS (creatinine >300 umol/L, RTX as induction) associated with increased risk of death, ESKD, progression before remission requiring treatment modification or relapse, Nagle S Abst#0725 #ACR23 #ACRBest @RheumNow https://t.co/ZVZYRnSy3n
Dr. Antoni Chan ( View Tweet)
What a talk. @DrPujaMehta1 on the big stage, with a truly inspirational talk in the #ACR23 Daltroy Lecture.
If you have any thoughts at all on DEI, or just are curious, you need to watch this.
I need to listen to it again, but two initial key points for me:
@RheumNow https://t.co/G4lngvpdS7
David Liew drdavidliew ( View Tweet)
Phase 2 RCT of TLL-018 (JAK1/TYK2i) vs Tofa in RA. 101 patients. ACR50 72% vs 42%. 83% of tofa-IR achieved ACR50 on TLL-018. Can't wait for the phase 3 data! Abstr#0840 #ACR23 @RheumNow #ACRbest https://t.co/wjGx4Edxyb https://t.co/n6CL8G01Wo
Richard Conway ( View Tweet)
Two initial points for me:
1. Challenge how we see all this, lot of current thinking misses the mark
2. Action, not just acknowledgement, but needs to be thoughtful about what it achieves, not just reactive
I’m not doing it justice. Listen to the whole thing!
#ACR23 @RheumNow https://t.co/ydb8COnqtA
David Liew drdavidliew ( View Tweet)
@Yuz6Yusof @RheumNow @EBRheum Look at all these @RheumNow people here in person #ACR23! https://t.co/aoxirYrxIU
David Liew drdavidliew ( View Tweet)